

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Telix Pharmaceuticals Limited
ABN	85 616 620 369

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Dr Christian Behrenbruch
Date of last notice	27 February 2025

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct interest
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	N/A
Date of change	6 March 2025
No. of securities held prior to change	<p>Direct Interest</p> <ul style="list-style-type: none"> • 553,298 fully paid ordinary shares (including 400,000 American Depository Shares (each representing 1 ordinary share) in Telix Pharmaceuticals Limited). • 100,708 share options with an exercise price of \$4.38 per option and an expiry date of 26 January 2026. Options vest upon achievement of \$100M in cumulative revenue from product sales. Options allotted following shareholder approval at the AGM held 12 May 2021 (TLX009 - TLXAL). • 139,672 Performance Share Appreciation Rights (notional exercise price \$4.95) (TLX012 - TLXAO) issued following shareholder approval at the AGM held 18 May 2022.

+ See chapter 19 for defined terms.

For personal use only

Appendix 3Y
Change of Director's Interest Notice

	<ul style="list-style-type: none"> • 120,268 Performance Share Appreciation Rights (notional exercise price \$6.90) (TLXO015 - TLXAO) issued following shareholder approval at the AGM held 24 May 2023. • 144,037 Performance Share Appreciation Rights (notional exercise price \$11.94) (TLXO024 - TLXAO) issued following shareholder approval at the AGM held 22 May 2024. <p>Indirect interest</p> <ul style="list-style-type: none"> • 20,675,000 fully paid ordinary shares (Elk River Holdings Pty Ltd as Trustee for The Behrenbruch Family Trust).
Class	Performance Share Appreciation Rights (notional exercise price \$4.95) (TLXO012 - TLXAO)
Number acquired	Nil
Number disposed	46,558
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Nil
No. of securities held after change	<p>Direct Interest</p> <ul style="list-style-type: none"> • 553,298 fully paid ordinary shares (including 400,000 American Depository Shares (each representing 1 ordinary share) in Telix Pharmaceuticals Limited). • 100,708 share options with an exercise price of \$4.38 per option and an expiry date of 26 January 2026. Options vest upon achievement of \$100M in cumulative revenue from product sales. Options allotted following shareholder approval at the AGM held 12 May 2021 (TLXO009 - TLXAL). • 93,114 Performance Share Appreciation Rights (notional exercise price \$4.95) (TLXO012 - TLXAO) issued following shareholder approval at the AGM held 18 May 2022. • 120,268 Performance Share Appreciation Rights (notional exercise price \$6.90) (TLXO015 - TLXAO) issued following shareholder approval at the AGM held 24 May 2023. • 144,037 Performance Share Appreciation Rights (notional exercise price \$11.94) (TLXO024 - TLXAO) issued following shareholder approval at the AGM held 22 May 2024. <p>Indirect interest</p> <ul style="list-style-type: none"> • 20,675,000 fully paid ordinary shares (Elk River Holdings Pty Ltd as Trustee for The Behrenbruch Family Trust).

+ See chapter 19 for defined terms.

For personal use only

Appendix 3Y
Change of Director's Interest Notice

Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Lapse of Performance Share Appreciation Rights as a result of testing and vesting of the 2022 Performance Share Appreciation Rights grant.
---	--

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

3 – ⁺Closed period Part

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.

For personal use only